Ubiquitin-proteasome dependent degradation of GABAAα1 in autism spectrum disorder

Amanda Crider, Chirayukumar D Pandya, Diya Peter, Anthony O. Ahmed, Anilkumar R Pillai

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Although the neurobiological basis of autism spectrum disorder (ASD) is not fully understood, recent studies have indicated the potential role of GABAAreceptors in the pathophysiology of ASD. GABAAreceptors play a crucial role in various neurodevelopmental processes and adult neuroplasticity. However, the mechanism(s) of regulation of GABAAreceptors in ASD remains poorly understood. Methods. Postmortem middle frontal gyrus tissues (13 ASD and 13 control subjects) were used. In vitro studies were performed in primary cortical neurons at days in vitro (DIV) 14. The protein levels were examined by western blotting. Immunofluorescence studies were employed for cellular localization. The gene expression was determined by RT-PCR array and qRT-PCR. Results: A significant decrease in GABAAα1 protein, but not mRNA levels was found in the middle frontal gyrus of ASD subjects indicating a post-translational regulation of GABAAreceptors in ASD. At the cellular level, treatment with proteasomal inhibitor, MG132, or lactacystin significantly increased GABAAα1 protein levels and Lys48-linked polyubiquitination of GABAAα1, but reduced proteasome activity in mouse primary cortical neurons (DIV 14 from E16 embryos). Moreover, treatment with betulinic acid, a proteasome activator significantly decreased GABAAα1 protein levels in cortical neurons indicating the role of polyubiquitination of GABAAα1 proteins with their subsequent proteasomal degradation in cortical neurons. Ubiquitination specific RT-PCR array followed by western blot analysis revealed a significant increase in SYVN1, an endoplasmic reticulum (ER)-associated degradation (ERAD) E3 ubiquitin ligase in the middle frontal gyrus of ASD subjects. In addition, the inhibition of proteasomal activity by MG132 increased the expression of GABAAα1 in the ER. The siRNA knockdown of SYVN1 significantly increased GABAAα1 protein levels in cortical neurons. Moreover, reduced association between SYVN1 and GABAAα1 was found in the middle frontal gyrus of ASD subjects. Conclusions: SYVN1 plays a critical role as an E3 ligase in the ubiquitin proteasome system (UPS)-mediated GABAAα1 degradation. Thus, inhibition of the ubiquitin-proteasome-mediated GABAAα1 degradation may be an important mechanism for preventing GABAAα1 turnover to maintain GABAAα1 levels and GABA signaling in ASD.

Original languageEnglish (US)
Article number45
JournalMolecular Autism
Volume5
Issue number1
DOIs
StatePublished - Sep 1 2014

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Neurons
Proteins
Ubiquitin-Protein Ligases
Polymerase Chain Reaction
Western Blotting
Endoplasmic Reticulum-Associated Degradation
Autism Spectrum Disorder
Neuronal Plasticity
Ubiquitination
Endoplasmic Reticulum
gamma-Aminobutyric Acid
Small Interfering RNA
Fluorescent Antibody Technique
Embryonic Structures
Gene Expression
Messenger RNA
Therapeutics

Keywords

  • Autism
  • GABAreceptor
  • Neurons
  • SYVN1
  • Ubiquitination

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Neuroscience
  • Developmental Biology
  • Psychiatry and Mental health

Cite this

Ubiquitin-proteasome dependent degradation of GABAAα1 in autism spectrum disorder. / Crider, Amanda; Pandya, Chirayukumar D; Peter, Diya; Ahmed, Anthony O.; Pillai, Anilkumar R.

In: Molecular Autism, Vol. 5, No. 1, 45, 01.09.2014.

Research output: Contribution to journalArticle

Crider, Amanda ; Pandya, Chirayukumar D ; Peter, Diya ; Ahmed, Anthony O. ; Pillai, Anilkumar R. / Ubiquitin-proteasome dependent degradation of GABAAα1 in autism spectrum disorder. In: Molecular Autism. 2014 ; Vol. 5, No. 1.
@article{cac5bce85c8041da855ffe5bc51bb2ad,
title = "Ubiquitin-proteasome dependent degradation of GABAAα1 in autism spectrum disorder",
abstract = "Background: Although the neurobiological basis of autism spectrum disorder (ASD) is not fully understood, recent studies have indicated the potential role of GABAAreceptors in the pathophysiology of ASD. GABAAreceptors play a crucial role in various neurodevelopmental processes and adult neuroplasticity. However, the mechanism(s) of regulation of GABAAreceptors in ASD remains poorly understood. Methods. Postmortem middle frontal gyrus tissues (13 ASD and 13 control subjects) were used. In vitro studies were performed in primary cortical neurons at days in vitro (DIV) 14. The protein levels were examined by western blotting. Immunofluorescence studies were employed for cellular localization. The gene expression was determined by RT-PCR array and qRT-PCR. Results: A significant decrease in GABAAα1 protein, but not mRNA levels was found in the middle frontal gyrus of ASD subjects indicating a post-translational regulation of GABAAreceptors in ASD. At the cellular level, treatment with proteasomal inhibitor, MG132, or lactacystin significantly increased GABAAα1 protein levels and Lys48-linked polyubiquitination of GABAAα1, but reduced proteasome activity in mouse primary cortical neurons (DIV 14 from E16 embryos). Moreover, treatment with betulinic acid, a proteasome activator significantly decreased GABAAα1 protein levels in cortical neurons indicating the role of polyubiquitination of GABAAα1 proteins with their subsequent proteasomal degradation in cortical neurons. Ubiquitination specific RT-PCR array followed by western blot analysis revealed a significant increase in SYVN1, an endoplasmic reticulum (ER)-associated degradation (ERAD) E3 ubiquitin ligase in the middle frontal gyrus of ASD subjects. In addition, the inhibition of proteasomal activity by MG132 increased the expression of GABAAα1 in the ER. The siRNA knockdown of SYVN1 significantly increased GABAAα1 protein levels in cortical neurons. Moreover, reduced association between SYVN1 and GABAAα1 was found in the middle frontal gyrus of ASD subjects. Conclusions: SYVN1 plays a critical role as an E3 ligase in the ubiquitin proteasome system (UPS)-mediated GABAAα1 degradation. Thus, inhibition of the ubiquitin-proteasome-mediated GABAAα1 degradation may be an important mechanism for preventing GABAAα1 turnover to maintain GABAAα1 levels and GABA signaling in ASD.",
keywords = "Autism, GABAreceptor, Neurons, SYVN1, Ubiquitination",
author = "Amanda Crider and Pandya, {Chirayukumar D} and Diya Peter and Ahmed, {Anthony O.} and Pillai, {Anilkumar R}",
year = "2014",
month = "9",
day = "1",
doi = "10.1186/2040-2392-5-45",
language = "English (US)",
volume = "5",
journal = "Molecular Autism",
issn = "2040-2392",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Ubiquitin-proteasome dependent degradation of GABAAα1 in autism spectrum disorder

AU - Crider, Amanda

AU - Pandya, Chirayukumar D

AU - Peter, Diya

AU - Ahmed, Anthony O.

AU - Pillai, Anilkumar R

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Background: Although the neurobiological basis of autism spectrum disorder (ASD) is not fully understood, recent studies have indicated the potential role of GABAAreceptors in the pathophysiology of ASD. GABAAreceptors play a crucial role in various neurodevelopmental processes and adult neuroplasticity. However, the mechanism(s) of regulation of GABAAreceptors in ASD remains poorly understood. Methods. Postmortem middle frontal gyrus tissues (13 ASD and 13 control subjects) were used. In vitro studies were performed in primary cortical neurons at days in vitro (DIV) 14. The protein levels were examined by western blotting. Immunofluorescence studies were employed for cellular localization. The gene expression was determined by RT-PCR array and qRT-PCR. Results: A significant decrease in GABAAα1 protein, but not mRNA levels was found in the middle frontal gyrus of ASD subjects indicating a post-translational regulation of GABAAreceptors in ASD. At the cellular level, treatment with proteasomal inhibitor, MG132, or lactacystin significantly increased GABAAα1 protein levels and Lys48-linked polyubiquitination of GABAAα1, but reduced proteasome activity in mouse primary cortical neurons (DIV 14 from E16 embryos). Moreover, treatment with betulinic acid, a proteasome activator significantly decreased GABAAα1 protein levels in cortical neurons indicating the role of polyubiquitination of GABAAα1 proteins with their subsequent proteasomal degradation in cortical neurons. Ubiquitination specific RT-PCR array followed by western blot analysis revealed a significant increase in SYVN1, an endoplasmic reticulum (ER)-associated degradation (ERAD) E3 ubiquitin ligase in the middle frontal gyrus of ASD subjects. In addition, the inhibition of proteasomal activity by MG132 increased the expression of GABAAα1 in the ER. The siRNA knockdown of SYVN1 significantly increased GABAAα1 protein levels in cortical neurons. Moreover, reduced association between SYVN1 and GABAAα1 was found in the middle frontal gyrus of ASD subjects. Conclusions: SYVN1 plays a critical role as an E3 ligase in the ubiquitin proteasome system (UPS)-mediated GABAAα1 degradation. Thus, inhibition of the ubiquitin-proteasome-mediated GABAAα1 degradation may be an important mechanism for preventing GABAAα1 turnover to maintain GABAAα1 levels and GABA signaling in ASD.

AB - Background: Although the neurobiological basis of autism spectrum disorder (ASD) is not fully understood, recent studies have indicated the potential role of GABAAreceptors in the pathophysiology of ASD. GABAAreceptors play a crucial role in various neurodevelopmental processes and adult neuroplasticity. However, the mechanism(s) of regulation of GABAAreceptors in ASD remains poorly understood. Methods. Postmortem middle frontal gyrus tissues (13 ASD and 13 control subjects) were used. In vitro studies were performed in primary cortical neurons at days in vitro (DIV) 14. The protein levels were examined by western blotting. Immunofluorescence studies were employed for cellular localization. The gene expression was determined by RT-PCR array and qRT-PCR. Results: A significant decrease in GABAAα1 protein, but not mRNA levels was found in the middle frontal gyrus of ASD subjects indicating a post-translational regulation of GABAAreceptors in ASD. At the cellular level, treatment with proteasomal inhibitor, MG132, or lactacystin significantly increased GABAAα1 protein levels and Lys48-linked polyubiquitination of GABAAα1, but reduced proteasome activity in mouse primary cortical neurons (DIV 14 from E16 embryos). Moreover, treatment with betulinic acid, a proteasome activator significantly decreased GABAAα1 protein levels in cortical neurons indicating the role of polyubiquitination of GABAAα1 proteins with their subsequent proteasomal degradation in cortical neurons. Ubiquitination specific RT-PCR array followed by western blot analysis revealed a significant increase in SYVN1, an endoplasmic reticulum (ER)-associated degradation (ERAD) E3 ubiquitin ligase in the middle frontal gyrus of ASD subjects. In addition, the inhibition of proteasomal activity by MG132 increased the expression of GABAAα1 in the ER. The siRNA knockdown of SYVN1 significantly increased GABAAα1 protein levels in cortical neurons. Moreover, reduced association between SYVN1 and GABAAα1 was found in the middle frontal gyrus of ASD subjects. Conclusions: SYVN1 plays a critical role as an E3 ligase in the ubiquitin proteasome system (UPS)-mediated GABAAα1 degradation. Thus, inhibition of the ubiquitin-proteasome-mediated GABAAα1 degradation may be an important mechanism for preventing GABAAα1 turnover to maintain GABAAα1 levels and GABA signaling in ASD.

KW - Autism

KW - GABAreceptor

KW - Neurons

KW - SYVN1

KW - Ubiquitination

UR - http://www.scopus.com/inward/record.url?scp=84906959764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906959764&partnerID=8YFLogxK

U2 - 10.1186/2040-2392-5-45

DO - 10.1186/2040-2392-5-45

M3 - Article

AN - SCOPUS:84906959764

VL - 5

JO - Molecular Autism

JF - Molecular Autism

SN - 2040-2392

IS - 1

M1 - 45

ER -